Time filter

Source Type

Grunblatt E.,University of Zürich | Grunblatt E.,ETH Zurich | Grunblatt E.,University of Würzburg | Riederer P.,University of Würzburg | Riederer P.,Institute Cognitive Brain science
Journal of Neural Transmission | Year: 2016

Evidence suggests that aldehyde dehydrogenase (ALDH; E.C. gene, protein expression and activity are substantially decreased in the substantia nigra of patients with Parkinson’s disease (PD). This holds especially true for cytosolic ALDH1A1, while mitochondrial ALDH2 is increased in the putamen of PD. Similarly, in Alzheimer’s disease (AD) several studies in genetic, transcriptomic, protein and animal models suggest ALDH involvement in the neurodegeneration processes. Such data are in line with findings of increased toxic aldehydes, like for example malondialdehyde, nonenal, 3,4-dihydroxyphenylacetaldehyde and others. Genetic, transcriptomic and protein alterations may contribute to such data. Also in vitro and in vivo experimental work points to an important role of ALDH in the pathology of neurodegenerative disorders. Aims at investigating dysfunctions of aldehyde detoxification are suitable to define genetic/molecular targets for new therapeutic strategies balancing amine metabolism in devastating disorders like PD and probably also AD. © 2014, Springer-Verlag Wien.

Bartl J.,University of Zürich | Muller T.,St Joseph Hospital Berlin Weissensee | Grunblatt E.,University of Zürich | Grunblatt E.,ETH Zurich | And 4 more authors.
Journal of Neural Transmission | Year: 2014

Patients with Parkinson's disease receive selective irreversible monoamine oxidase (MAO)-B inhibitors, but their effects on MAO-A activity are not known during long-term application. We determined MAO-A inhibition in plasma samples from patients with MAO-B inhibitor intake or without MAO-B inhibitor treatment and from healthy controls. We detected a 70 % reduction of MAO-A activity in patients with MAO-B inhibitor therapy in comparison to the other groups. Our results suggest that treatment with MAO-B inhibitor may also influence MAO-A activity in vivo, when administered daily. © 2013 Springer-Verlag Wien.

Loading Institute Cognitive Brain science collaborators
Loading Institute Cognitive Brain science collaborators